Contents

Preface —— V

Chapter 1
Analytical chemistry in biopharma —— 1
References —— **8**

Chapter 2
A brief overview of biological mass spectrometry: concepts and definitions —— 11
2.1 Mass measurements: stable isotopes, isotopic distributions, ionic and molecular masses, and mass resolution —— **11**
2.2 Generation of macromolecular ions: matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) —— **16**
2.3 Ion fragmentation: tandem mass spectrometry —— **22**
2.4 Ion manipulation in electromagnetic fields: mass analyzers —— **26**
2.4.1 Quadrupole mass filters and triple-quadrupole MS —— **27**
2.4.2 Quadrupole (3-D) and linear ion traps —— **28**
2.4.3 Time-of-flight MS —— **29**
2.4.4 Fourier transform MS: ion cyclotron resonance and Orbitrap mass analyzers —— **30**
2.4.5 Hybrid mass spectrometers —— **31**
References —— **32**

Chapter 3
Characterization of covalent structure of protein therapeutics —— 37
3.1 Amino acid sequence analysis and characterization of sequence variant types —— **37**
3.1.1 Confirmation of the amino acid sequence of protein biopharmaceuticals by intact mass measurements —— **37**
3.1.2 Confirmation of the amino acid sequence of protein therapeutics by peptide mapping analysis —— **40**
3.1.3 Confirmation of the primary sequence of protein therapeutics by top-down MS analysis —— **47**
3.2 Characterization of enzymatic post-translational modifications —— **51**
3.2.1 N-Glycosylation —— **53**
3.2.2 O-Glycosylation —— **61**
3.2.3 Disulfide bonds and disulfide scrambling —— **61**
3.2.4 Other enzymatic PTMs —— **67**

Bibliografische Informationen
http://d-nb.info/1182483968

digitalisiert durch DEUTSCHE NATIONAL BIBLIOTHEK

3.3 Characterization of non-enzymatic PTMs — **69**
3.3.1 Asparagine deamidation and aspartic acid isomerization — **70**
3.3.2 Oxidation — **76**
3.3.3 Lysine and N-terminal amine glycation — **78**
3.3.4 N-Terminal glutamate to pyroglutamate conversion — **83**
3.3.5 Protein backbone cleavage — **84**
3.4 "Designer" PTMs (chemical conjugation products) and methods of their characterization — **84**
3.4.1 Protein PEGylation and other protein–polymer conjugates — **85**
3.4.2 Protein–small-molecule drug conjugates — **89**
3.4.3 Protein–protein conjugates — **91**
References — **91**

Chapter 4
Characterization of higher order structure and protein interactions — 101
4.1 Mass spectrometry and its place in the analytical toolbox used for higher order structure characterization of protein therapeutics — **101**
4.2 Native electrospray ionization MS — **103**
4.2.1 Protein ion charge state distributions: conformational integrity of monomeric proteins — **103**
4.2.2 Native mass spectrometry and non-covalent assemblies: protein quaternary structure and interactions of protein therapeutics with their targets and physiological partners — **105**
4.2.3 Native mass spectrometry of highly heterogeneous protein therapeutics — **111**
4.2.4 Can native MS be used to provide quantitative information on interactions between protein therapeutics and their targets? — **117**
4.2.5 What needs to be considered at the planning stage and/or when analyzing the results of native MS measurements — **118**
4.3 Hydrogen deuterium exchange (HDX) MS — **122**
4.3.1 Global HDX MS measurements to monitor conformational integrity of protein therapeutics — **122**
4.3.2 Site-specific HDX MS measurements to identify instability hot spots — **125**
4.3.3 Site-specific HDX MS measurements to localize binding interfaces — **127**
4.3.4 HDX MS to probe aggregation of protein therapeutics — **129**
4.3.5 What needs to be considered at the planning stage and/or when analyzing the results of HDX MS measurements — **129**
4.3.6 Spatial resolution in site-specific HDX MS measurements and methods to improve it — **130**

4.4 Covalent labeling methods — 131
4.4.1 Chemical labeling and cross-linking: what limits their use in characterization of biopharmaceutical products? — 132
4.4.2 Characterization of protein higher order structure with FPOP — 133
4.5 An outlook for MS-based methods to probe higher order structure of protein therapeutics — 135
References — 136

Chapter 5
Biosimilars and comparability studies — 145
5.1 Biogenerics or biosimilars? — 145
5.2 MS-based characterization of the covalent structure in the biosimilarity assessments — 147
5.3 MS-based characterization of the higher order structure in the biosimilarity assessments — 152
5.4 MS-based characterization of the purity in biosimilarity assessments — 155
References — 155

Chapter 6
Characterization of impurities in biopharmaceutical products — 159
6.1 Product-related substances and impurities — 159
6.2 Characterization of size variants of protein biopharmaceuticals — 159
6.2.1 MS-based characterization of size variants under denaturing conditions — 160
6.2.2 MS-based characterization of size variants under non-denaturing conditions — 161
6.2.3 MS-based characterization of protein aggregates — 164
6.3 MS-based characterization of charge variants of protein biopharmaceuticals — 165
6.4 MS-based characterization of homodimer impurities in bispecific mAbs — 169
6.5 Process-related impurities: MS-based characterization of host cell proteins — 172
6.6 Viral and microbial contaminants: adventitious agents and bioburden — 174
6.7 Formulation-related impurities — 177
References — 179

Chapter 7
Quantitation of protein therapeutics in biological samples — 183
7.1 What motivates the development of MS-based quantitation strategies for protein therapeutics? — **183**
7.2 Quantitation with and without internal standards — **185**
7.3 Protein quantitation using surrogate peptides — **187**
7.4 Protein quantitation at intact and subunit levels — **192**
7.5 Protein quantitation using metal tags — **199**
7.6 Biodistribution study of protein drugs by mass spectrometry imaging — **200**
References — **203**

Chapter 8
Non-protein biopharmaceuticals and related macromolecular drugs — 207
8.1 Nucleic acid–based therapeutics: MS characterization of small nucleic acids (antisense therapeutics and aptamers) — **207**
8.2 Macromolecular natural products: heparin and related medicines — **215**
8.3 MS in the analytical support of gene therapies — **222**
8.4 MS in the analytical support of cell-based therapies — **233**
8.5 MS in characterization of modern vaccines — **233**
8.6 MS in characterization of nanomedicines — **235**
References — **236**

Chapter 9
What is next? — 243
9.1 The emerging role of mass spectrometry in process analytical technology — **243**
9.2 Mass spectrometry in personalized medicine — **247**
References — **249**

Index — 251